Intermediate endpoint biomarkers for chemoprevention

Area of Science:

• Oncology
• Biochemistry
• Molecular Biology

Background:

• Intermediate endpoint biomarkers are crucial for evaluating chemopreventive agents in bladder cancer.
• Biomarkers can be genotypic or phenotypic and indicate susceptibility, exposure, effect, or disease.
• Understanding biomarker expression aids in monitoring chemoprevention therapy.

Purpose of the Study:

• To investigate the role of nuclear size and DNA ploidy as intermediate endpoint biomarkers in bladder tumorigenesis.
• To explore the potential of cytoskeletal biomarkers, like F-actin, in assessing bladder cancer risk and chemoprevention.
• To elucidate the sequence of phenotypic biomarker expression during bladder cancer development.

Main Methods:

• Animal studies using N-butyl-N-(4-hydroxybutyl)nitrosamine (OH-BBN) and N-(4-hydroxyphenyl)retinamide (4-HPR) in mice.
• In vitro studies with cell lines (RPMI-7666, HL-60) treated with retinoids and other agents.
• Clinical evaluation of F-actin and other biomarkers in bladder cancer patients.

Main Results:

• 4-HPR affected tumor differentiation, nuclear size, and DNA ploidy, suggesting their utility as biomarkers.
• F-actin normalized in cells treated with 4-HPR or DMSO, and its clinical evaluation confirmed its value in bladder cancer risk assessment.
• G-actin increased early in oncogenesis, preceding other biomarkers like p300 antigen, EGFR, p185, DNA aneuploidy, and visual morphology.

Conclusions:

• Nuclear size and DNA ploidy are potential intermediate endpoint biomarkers for bladder cancer.
• Cytoskeletal biomarkers like F-actin are valuable for bladder cancer risk assessment and monitoring chemoprevention.
• The sequence of phenotypic biomarker expression provides insights into the mechanisms of bladder cancer oncogenesis.